Laboratoire Aguettant in the news

French President Emmanuel Macron visited Laboratoire Aguettant to discuss the health industry and industrial sovereignty.

The Aguettant family has a long history in pharmaceuticals through Laboratoire Aguettant, specializing in injectable solutions, and Sébastien Aguettant's Delpharm, a major contract manufacturer that grew significantly during the pandemic.

Philippe de Pougnadoresse will become the new CEO of the Lyon-based pharmaceutical group Aguettant in July 2026 to drive international growth in injectable medicines.

Laboratoire Aguettant employs 665 people and has seen a 3.7% annual increase in its workforce.

Sébastien Aguettant's family controls Laboratoire Aguettant, an injectable solutions specialist, which saw its valuation increase during COVID-19, while his Delpharm acquisition became a top pharmaceutical subcontractor.

Aguettant uses the Projet Voltaire to enhance all employees' French language skills, boosting communication, confidence, and team cohesion.

Aguettant Ltd partners with Movianto UK to manage warehousing and distribution of infusion solutions for NHS hospitals, following Laboratoire Aguettant's acquisition of Carelide.

Aguettant Ltd has outsourced its infusion solution logistics to Movianto, which manages the full supply chain under temperature-controlled conditions in the UK.

Aguettant is investing €31 million to boost injectable drug production capacity at its Lyon and Ardèche sites, aiming to increase annual output and expand logistics facilities by 2024.

Aguettant is expanding its Lyon and Ardèche sites to boost production of injectable syringes and ampoules.

Laboratoire Aguettant is significantly expanding its injectable drug production capacity and international presence, backed by major investments and government support.

Aguettant is investing €31.1 million to expand production of key hospital injectable drugs in France, supported by government funding and aiming to increase capacity and workforce.

Aguettant is investing €31 million to expand production capacity for key injectable drugs in Lyon and Ardèche, accelerating growth under the France2030 relocalization plan.

The French government is actively supporting pharmaceutical sovereignty by investing in local production, innovation, and relocalization of essential medicines, with companies like Aguettant playing a key role.

Emmanuel Macron announced a plan to re-shore drug production, with four pharmaceutical sites in the Auvergne-Rhône-Alpes region, including Laboratoire Aguettant, receiving substantial investments.

French President Emmanuel Macron visited Laboratoire Aguettant to discuss French industrial sovereignty and the health industry.

President Macron visited Laboratoire Aguettant in Ardèche, highlighting the company's regional importance.

President Macron is visiting Laboratoire Aguettant to announce a 45 million euro investment to boost French production of anesthesia medications.

Delpharm and Laboratoire Aguettant jointly acquired Carelide, preserving jobs and expanding capabilities in infusion bag production with government support.

Delpharm and Laboratoire Aguettant jointly acquired Carelide, the sole French infusion bag maker, investing heavily to modernize its operations and preserve jobs with government support.